Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/o…
📬 Get email alerts for new Grants & Fellowships
Free — we'll email you when new matching opportunities appear. No spam, unsubscribe anytime.
New here? Here's how Reward Opportunity works:
🎓 More Grants & Fellowships
Government, corporate, and nonprofit grants open to individuals, researchers, and small businesses.
Browse all grants & fellowships →Not just this one — find everything you qualify for
Our AI scans 8,000+ bounties, settlements, grants, recalls, and paid studies against your profile to rank what you can actually claim.
Get My Free Match Report